Other equities research analysts also recently issued reports about the company. Liberum Capital restated a buy rating and issued a GBX 1,900 ($25.45) price target on shares of GlaxoSmithKline in a report on Wednesday, August 30th. Jefferies Group lowered their price target on GlaxoSmithKline from GBX 1,900 ($25.45) to GBX 1,750 ($23.44) and set a buy rating for the company in a report on Thursday, August 24th. Berenberg Bank lowered their price target on GlaxoSmithKline from GBX 1,885 ($25.24) to GBX 1,835 ($24.57) and set a buy rating for the company in a report on Wednesday, August 9th. restated a buy rating and issued a GBX 1,970 ($26.38) price target on shares of GlaxoSmithKline in a report on Wednesday, September 13th. Finally, Beaufort Securities restated a buy rating and issued a GBX 1,800 ($24.11) price target on shares of GlaxoSmithKline in a report on Monday, October 23rd. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of Hold and an average price target of GBX 1,581.90 ($21.19).
Shares of GlaxoSmithKline (LON GSK) opened at GBX 1,295 ($17.34) on Friday. GlaxoSmithKline has a fifty-two week low of GBX 1,277.50 ($17.11) and a fifty-two week high of GBX 1,724.50 ($23.09).
The company also recently disclosed a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be issued a dividend of GBX 19 ($0.25) per share. The ex-dividend date is Thursday, November 9th. This represents a dividend yield of 1.41%.
In other news, insider Urs Rohner acquired 473 shares of the firm’s stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average cost of GBX 1,518 ($20.33) per share, for a total transaction of £7,180.14 ($9,615.83). Also, insider Simon Dingemans acquired 1,076 shares of the firm’s stock in a transaction that occurred on Thursday, October 12th. The shares were purchased at an average price of GBX 1,527 ($20.45) per share, with a total value of £16,430.52 ($22,004.18). Over the last quarter, insiders have purchased 1,576 shares of company stock valued at $2,400,376.
COPYRIGHT VIOLATION WARNING: “Goldman Sachs Group Analysts Give GlaxoSmithKline (GSK) a GBX 1,775 Price Target” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://www.com-unik.info/2017/12/04/goldman-sachs-group-analysts-give-glaxosmithkline-gsk-a-gbx-1775-price-target.html.
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.